TD Waterhouse Canada Inc. Sells 21,342 Shares of Sanofi $SNY

TD Waterhouse Canada Inc. lessened its stake in shares of Sanofi (NASDAQ:SNY) by 8.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 219,429 shares of the company’s stock after selling 21,342 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Sanofi were worth $9,140,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of SNY. Physician Wealth Advisors Inc. increased its position in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after acquiring an additional 379 shares during the last quarter. Western Wealth Management LLC bought a new stake in shares of Sanofi in the 1st quarter worth about $29,000. Leonteq Securities AG lifted its holdings in shares of Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after acquiring an additional 297 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in shares of Sanofi during the 3rd quarter worth about $29,000. Finally, Palisade Asset Management LLC purchased a new position in shares of Sanofi during the 3rd quarter worth about $30,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.2%

Shares of SNY opened at $44.24 on Friday. The firm has a fifty day moving average price of $43.92 and a 200-day moving average price of $44.70. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $107.26 billion, a P/E ratio of 23.16, a P/E/G ratio of 1.34 and a beta of 0.35. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company had revenue of $13.36 billion for the quarter. During the same period in the prior year, the business earned $3.24 EPS. The company’s quarterly revenue was up 16.0% on a year-over-year basis. Equities research analysts expect that Sanofi will post 5.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on SNY shares. Morgan Stanley set a $49.00 price objective on shares of Sanofi in a research report on Wednesday, July 8th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 29th. Finally, Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of “Hold” and a consensus price target of $49.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.